To access the live webcast of bluebird bio's presentation, please visit the "Calendar of Events" page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the conference and the presentation will be available for download immediately following the presentation.
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing
potentially transformative gene therapies for severe genetic and orphan
diseases. bluebird bio has two clinical-stage programs in development.
The most advanced product candidate, Lenti-D, is in a Phase 2/3 study,
the Starbeam Study, for the treatment of childhood cerebral
adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder
affecting young boys. The next most advanced product candidate,
LentiGlobin, is currently in two Phase 1/2 studies for the treatment of
beta-thalassemia major, one in
bluebird bio has operations in
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of, and anticipated milestones
related to the Company’s product candidates. Any forward-looking
statements are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk of cessation or
delay of any of the ongoing or planned clinical studies and/or our
development of our product candidates, the risk of a delay in the
enrollment of patients in the Company’s clinical studies, the risk that
the results of previously conducted studies involving similar product
candidates will not be repeated or observed in ongoing or future studies
involving current product candidates, the risk that our collaboration
with
Source: bluebird bio, Inc.
Investor Relations
Pure Communications, Inc.
Matt
Clawson, 949-370-8500
or
Media Contact
Pure
Communications, Inc.
Dan Budwick, 973-271-6085